DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Virgin Coconut Oil Oral Supplementation for Leprosy Patients

Information source: Philippine Dermatological Society
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hansen's Disease

Intervention: Multi-Drug Therapy (Novartis Ⓡ) (Other); Virgin Coconut Oil (Dietary Supplement)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Philippine Dermatological Society

Overall contact:
Carmela F. Dayrit, MD, Phone: +63917-8995847, Ext: -, Email: miya_day@yahoo.com

Summary

To date, there has been no clinical investigation on the effects of virgin coconut oil (VCO) oral supplementation on patients with Hansen's disease (HD) undergoing medical treatment. This study aims to examine the possible protective effect of exogenous supplementation of VCO on the oxidative stress, antioxidant status, and treatment response among HD patients. Treatment response will be defined as the clinical changes in cutaneous and neurologic manifestations as measured by the clinical response score. This study also aims to investigate the potential of VCO as an adjunct to Multi-Drug Therapy (MDT) in mitigating lepra reactions.

Clinical Details

Official title: The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care

Primary outcome:

Change in Bacterial Indices

Change in Oxidative Stress Markers

Secondary outcome:

Change in Clinical Response Score (CRS)

Lepra reactions

Detailed description: Objective: To determine the effect of co-administration of virgin coconut oil (VCO) oral supplementation and standard Multi-Drug Therapy (MDT) on malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH) blood levels and to determine and compare treatment response between leprosy cases treated with MDT alone and cases treated with MDT with VCO supplementation. Design: This is an open label, controlled clinical trial and a preliminary/phase 1 trial. Setting: Patients seen in the out-patient clinic of the Section of Dermatology, Philippine General Hospital, a tertiary government hospital. Participants: Twenty-six previously untreated Hansen's Disease (HD) patients, 18 years old and above, diagnosed clinically and confirmed histologically with HD. Intervention: The 26 HD patients will be divided into two groups: group 1 will receive only MDT and group 2 will receive MDT with VCO supplementation. Both groups 1 and 2 will consist of 6 or 7 Paucibacillary (PB) patients and 6 or 7 Multibacillary (MB) patients. All participants will have MDA, SOD, and GSH blood levels taken on initial consult and on the third and sixth months. Treatment response will be measured by a clinical response score, which will be graded by a blinded investigator based on cutaneous manifestations (no change, moderate improvement, definite improvement, worse) and neurologic manifestations (no change, improvement, worse). Main Outcome Measures: The mean and inter-quartile range of MDA, SOD, and GSH blood levels; bacterial index (BI) and morphological index (MI) from slit skin-smears; and treatment response based on the clinical response score. Frequency and severity of lepra reactions will also be noted. Data Analysis: The following statistical tests will be used: Mann-Whitney test to compare the difference between median values of group 1 and group 2; Kruskal-Wallis Test for multiple comparisons; Wilcoxon signed ranks test for comparing differences in median values within groups; Fisher's exact test to compare the frequency of categorical data of treatment response (cutaneous manifestations); and T test for the quantitative data (neurologic manifestations) will be used. Values of p<0. 05 will be considered statistically significant.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients aged 18 years and above, male or female

- Patients with clinical evidence and histological confirmation of lepromatous leprosy

(LL), borderline lepromatous leprosy (BL), borderline leprosy (BB), borderline tuberculoid leprosy (BT), or tuberculoid leprosy (TT) according to the Ridley and Jopling classification and Paucibacillary (PB) or Multibacillary (MB) disease based on the World Health Organization (WHO) classification

- Patients should not have been on MDT in the past

- Patients with normal blood test results for complete blood count (CBC), liver

aminotransaminases (AST, ALT), glucose-6-phosphate dehydrogenase (G6PD) assay, creatinine, lipid profile and chest x-ray Exclusion Criteria:

- HD patients with reactions needing prednisone therapy at time of diagnosis

- Patients who are already taking VCO or any other oral or intravenous antioxidant

supplements

- Patients taking long term medications unrelated to leprosy

- Pregnant women

- Patients with history of smoking, co-infections such as tuberculosis, diabetes

mellitus, any other systemic diseases or health problems

- Patients not willing to return for follow-up

Locations and Contacts

Carmela F. Dayrit, MD, Phone: +63917-8995847, Ext: -, Email: miya_day@yahoo.com

Philippine General Hospital, Manila 1000, Philippines; Active, not recruiting

Philippine General Hospital, Manila 1000, Philippines; Recruiting
Josef Symon S Concha, MD, Phone: 5548400, Email: symonconcha.md@gmail.com
Carmela Augusta F Dayrit, MD DPDS, Phone: 5548400, Email: miya_day@yahoo.com

Additional Information

Starting date: June 2013
Last updated: April 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017